Skip to main content

NCT00249132 - A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients

A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients

Data Request Dashboard

Operations

No data requests found. Click here to generate a new one.


Data Specification

Not Available


Annotated CRF

Not Available

Product Info

Generic Name
Risperidone
Product Name
RISPERDAL®
Therapeutic Area
Behaviors and Mental Disorders
Enrollment
523
% Female
N/A
% White
N/A
Product Class
Atypical Antipsychotics
Sponsor Protocol Number
RIS-INT-3
Data Holder
Johnson & Johnson
Condition Studied
Schizophrenia
Mean/Median Age (Years)
N/A

Supporting Documentation

Analysis Datasets
Data Definition Specification Available
Annotated Case Report Form Available
Clinical Study Report
Protocol with Amendments
Study Phase 
3

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.